Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st 3 Qtrs Business Results
February 21, 2005
- 2/3 of Ethical Drugs Designated as "Rx-only Drugs"
February 21, 2005
- Korosho to Demand PIII Data in NDA for Anticancer Agents
February 21, 2005
- Handling of Applications for Add'l Indications of Anticancer Drugs Notified
February 21, 2005
- Add. Indications Approved for 45 Drugs Used Off-label: JAPIC Seminar
February 21, 2005
- REGULATORY NEWS IN BRIEF
February 21, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 21, 2005
- MONITOR
February 21, 2005
- Aiming at Acquiring "Absolute No.1" in Diagnostic Market: Mr Ogawa of RDKK
February 21, 2005
- The Society of Japanese Pharmacopoeia Seminar
February 21, 2005
- OTC NEWS IN BRIEF
February 21, 2005
- Kringle, Galeni Make Research Evaluation Accord
February 21, 2005
- FPMAJ's GL on Handling of Personal Information Announced
February 21, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 21, 2005
- JPEC to Start GMP Compliance Certification for Pharm. Excipients
February 21, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 21, 2005
- Alfresa to Train MSs to Help Boost Profits, Cut Costs
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 1st 3Qtrs Business Results
February 14, 2005
- Drug Administration Is at Crossroads: New GAD Director
February 14, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…